title: New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol.
abstract: The pathogenesis of psoriatic arthritis (PsA) is still under discussion but great advances have been made in the last 2 decades that confirm the central role of tumor necrosis factor-α (TNF-α) in its inflammatory milieu. New therapeutic approaches have been proposed, and new molecules with anti-TNF-α activity have been chemically altered to improve their pharmacological properties. Certolizumab pegol (CZP) is a PEGylated Fc-free anti-TNF that has been shown clinically to be effective in the treatment of rheumatoid arthritis (RA), skin psoriasis, and PsA. This article summarizes available data on its clinical efficacy and safety profile in the treatment of patients with PsA.
authors.affiliation: From the Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Monserrato; Rheumatology Unit, Department of Medicine and Health Sciences, University of Molise, Campobasso; and Azienda Ospedaliero-Universitaria, Day Hospital di Reumatologia, Istituto Ortopedico G. Pini, Milan, Italy.A. Cauli, MD, PhD; M. Piga, MD, Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari; E. Lubrano, MD, PhD, Rheumatology Unit, Department of Medicine and Health Sciences, University of Molise; A. Marchesoni, MD, Azienda Ospedaliero-Universitaria, Day Hospital di Reumatologia, Istituto Ortopedico G. Pini; A. Floris, MD; A. Mathieu, MD, Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari. cauli@medicina.unica.it.
authors.forename: Alberto
authors.initials: A
authors.lastname: Cauli
authors.affiliation: From the Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Monserrato; Rheumatology Unit, Department of Medicine and Health Sciences, University of Molise, Campobasso; and Azienda Ospedaliero-Universitaria, Day Hospital di Reumatologia, Istituto Ortopedico G. Pini, Milan, Italy.A. Cauli, MD, PhD; M. Piga, MD, Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari; E. Lubrano, MD, PhD, Rheumatology Unit, Department of Medicine and Health Sciences, University of Molise; A. Marchesoni, MD, Azienda Ospedaliero-Universitaria, Day Hospital di Reumatologia, Istituto Ortopedico G. Pini; A. Floris, MD; A. Mathieu, MD, Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari.
authors.forename: Matteo
authors.initials: M
authors.lastname: Piga
authors.affiliation: From the Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Monserrato; Rheumatology Unit, Department of Medicine and Health Sciences, University of Molise, Campobasso; and Azienda Ospedaliero-Universitaria, Day Hospital di Reumatologia, Istituto Ortopedico G. Pini, Milan, Italy.A. Cauli, MD, PhD; M. Piga, MD, Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari; E. Lubrano, MD, PhD, Rheumatology Unit, Department of Medicine and Health Sciences, University of Molise; A. Marchesoni, MD, Azienda Ospedaliero-Universitaria, Day Hospital di Reumatologia, Istituto Ortopedico G. Pini; A. Floris, MD; A. Mathieu, MD, Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari.
authors.forename: Ennio
authors.initials: E
authors.lastname: Lubrano
authors.affiliation: From the Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Monserrato; Rheumatology Unit, Department of Medicine and Health Sciences, University of Molise, Campobasso; and Azienda Ospedaliero-Universitaria, Day Hospital di Reumatologia, Istituto Ortopedico G. Pini, Milan, Italy.A. Cauli, MD, PhD; M. Piga, MD, Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari; E. Lubrano, MD, PhD, Rheumatology Unit, Department of Medicine and Health Sciences, University of Molise; A. Marchesoni, MD, Azienda Ospedaliero-Universitaria, Day Hospital di Reumatologia, Istituto Ortopedico G. Pini; A. Floris, MD; A. Mathieu, MD, Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari.
authors.forename: Antonio
authors.initials: A
authors.lastname: Marchesoni
authors.affiliation: From the Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Monserrato; Rheumatology Unit, Department of Medicine and Health Sciences, University of Molise, Campobasso; and Azienda Ospedaliero-Universitaria, Day Hospital di Reumatologia, Istituto Ortopedico G. Pini, Milan, Italy.A. Cauli, MD, PhD; M. Piga, MD, Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari; E. Lubrano, MD, PhD, Rheumatology Unit, Department of Medicine and Health Sciences, University of Molise; A. Marchesoni, MD, Azienda Ospedaliero-Universitaria, Day Hospital di Reumatologia, Istituto Ortopedico G. Pini; A. Floris, MD; A. Mathieu, MD, Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari.
authors.forename: Alberto
authors.initials: A
authors.lastname: Floris
authors.affiliation: From the Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Monserrato; Rheumatology Unit, Department of Medicine and Health Sciences, University of Molise, Campobasso; and Azienda Ospedaliero-Universitaria, Day Hospital di Reumatologia, Istituto Ortopedico G. Pini, Milan, Italy.A. Cauli, MD, PhD; M. Piga, MD, Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari; E. Lubrano, MD, PhD, Rheumatology Unit, Department of Medicine and Health Sciences, University of Molise; A. Marchesoni, MD, Azienda Ospedaliero-Universitaria, Day Hospital di Reumatologia, Istituto Ortopedico G. Pini; A. Floris, MD; A. Mathieu, MD, Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Mathieu
mesh_terms: D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D001688:Biological Products / Q000009:adverse effects / Q000627:therapeutic use*; D000068582:Certolizumab Pegol / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology
chemical_list: D018501:Antirheumatic Agents; D001688:Biological Products; D014409:Tumor Necrosis Factor-alpha; D000068582:Certolizumab Pegol
keywords: CERTOLIZUMAB PEGOL; PSORIATIC ARTHRITIS; THERAPY